Program
19 September 2018
Registration
19 September 2018
ISPOR HTA Roundtable - MEA
Description
- By Invitation Only
19 September 2018
ISPOR Arabic Network Meeting
Description
- By Invitation Only
19 September 2018
Exhibition Open
19 September 2018
Educational Symposium
Description
How Real World Evidence Can Inform And Improve Healthcare Decision-Making In The Middle East
The symposium will provide an overview of the increasing need and use of Real World Evidence (RWE) by different stakeholders in the Middle East, and present the benefits of RWE generation capabilities to inform and improve healthcare decision making in the Middle East. The symposium will include a panel discussion involving senior representatives of various regional payers, HTA agencies and academic bodies. Panelists will provide their experience with RWE, in particular the value of RWE in their decision making and how they can be leveraged further.
Symposium sponsor is Amgen
19 September 2018
Educational Seminar: Introduction to Health Economics
Description
The session will introduce you to health economics as a sub-discipline of economics and its relevance to decision making in the healthcare sector.
The first part of the session will provide an overview of the principal concepts and theoretical foundations of health economics and how these help us to understand how healthcare markets work; the various market failures that can arise in healthcare; and the role of governments in regulating, funding and providing healthcare.
The second part of the session will introduce the methods and use of economic evaluation of healthcare, and how these can be used to assess value for money in decisions affecting the allocation of health care budgets.
Speakers
- Nancy Devlin, PhD
19 September 2018
Coffee Break
19 September 2018
Educational Seminar: Introduction to HTA
Description
This session will introduce health technology assessment (HTA), the context of how it fits into healthcare decision-making and its relevance to evidence based health policy and the implementation of efficient healthcare.
After providing an overview of the HTA journey (including horizon scanning), the key models and components of HTA, including health economics, different approaches of HTA implementation will be presented, including the initiative of the European Union for HTA collaboration.
The session will explore which HTA deliverables are more transferable across countries to reduce duplication of efforts.
Finally the session will introduce the concept of extended value framework for health technologies, and how the transparency and consistency of decisions may be improved by applying multi-criteria decision analysis (MCDA) based on different domains of HTA and the value framework.
19 September 2018
Welcome Reception
Description
In cooperation with The Department of Tourism and Commerce Marketing (DTCM) – Dubai Business Events
20 September 2018
Registration
20 September 2018
Exhibition Open
20 September 2018
Educational Symposium
Description
Time To Re-Think Approaches To Patient Centricity: Why Developments In Data Availability, Access To Medicines & Company Pipelines Demand This
The presentation and interaction during the seminar will address the following aspects of patient centricity approaches:
- How market dynamics are enhancing the need for patient centricity.
- The impact of specialist and rare disease medicines
- What does it mean to be patient centric across the lifecycle and how does this equate with commercial strategies?
- What is the practical utility of patient centricity in relation to the key challenges of access and value demonstration?
- Patient centric endpoints and value assessment: where this plays in the regulatory process
- The opportunities with data in the digital age
- How will industry know if it is being patient centric and the keys to success
Symposium sponsor is IQVIA
20 September 2018
Welcome Refreshments
20 September 2018
Welcome and Opening Remarks
Speakers
- Nancy S. Berg
- HE Dr Amin Al Ameeri
20 September 2018
Role of HEOR in Decision Making: Global Knowledge for Local Application
Description
This session will discuss the role which health economics and outcomes research plays in healthcare decisions, drawing on the experience of the United Kingdom, USA, United Arab Emirates and Egypt.
20 September 2018
Coffee Break
20 September 2018
Improving Access to Innovative Health Technologies
Description
Healthcare policy makers across the region are currently exploring options to establish HTA in their country. Frequently, opportunities and limitations of HTA to effectively address decision-making objectives and constraints are not well characterized or understood.
Process of improving patient access to innovative health technologies can benefit from alignment of realistic expectations towards HTA and evidence-informed decision- making.
During this session the following aspects, among others, will be addressed form the multi-stakeholder perspective:
- highlight the need to systematically align the expectations of patients, their caregivers and wider society towards collectively funded healthcare systems in light of available healthcare resources by means of evidence-informed decision processes
- stress the complementary need for healthcare systems to introduce aligned incentives for healthcare decision makers, providers, and patients to continuously improve the cost-effectiveness of innovative healthcare technologies over time
- share learnings and best practice with a specific focus on the opportunities and limitations of active stakeholder engagement in HTA (patients, providers and industry)
20 September 2018
Lunch and Prayer Time
20 September 2018
Pricing and Reimbursement: Issues and Challenges
Description
The objective of the session will be to highlight and discuss a number of significant challenges in pricing and reimbursement facing the countries in the region, in their pursuit to contain costs, improve efficient allocation of resources and enable faster access to new therapies. Specifically, the panel will discuss the following themes:
- the extent to which external reference pricing constitutes efficient regulation to promote efficiency and aligns public expectations with economic reality;
- the challenges and opportunities for reimbursement systems for pharmaceuticals in the Middle East and North Africa and ways to improve coverage;
- a review of the value assessment criteria for new therapies and how they are used in different settings;
- how innovative payment schemes and risk sharing, including coverage with evidence development, can be incorporated in decision-making processes in the region and what does the European / international experience suggest about their use.
20 September 2018
Coffee Break
20 September 2018
HTA Implementation Roadmap in the Middle East and North Africa
Description
The costs associated with opportunities forgone in inappropriate health policy decisions is especially high in countries with economic recession. Application of health technology assessment (HTA) informing policy decisions (eg, pricing, reimbursement) can improve the allocative efficiency of scarce resources contributing to optimal distribution of goods and services while taking into account patients’ and consumers’ preferences. Development and implementation of an HTA system could benefit from the knowledge transfer from other countries where such a system has been established thus, eg, avoiding the mistakes the others made. At the same time, realistic assessment of the specific economic and governance situations in the countries of the MENA region must be considered when developing an appropriate roadmap for HTA implementation responsive to the local needs.
This session aims to describe the main HTA implementation scenarios in the MENA countries and summarize the most important questions related to capacity building, financing HTA, process and organizational structure for HTA, standardization of HTA methodology, use of local data, scope of mandatory HTA, and decision criteria. The panel session – including introductory presentation and roundtable discussion – will help clarifying (1) long-term objectives and (2) immediate possible steps of HTA implementation in the MENA region.
20 September 2018
Day's Reflections: Bridging the Past and the Future
20 September 2018
Educational Symposium
Description
Harnessing The Power Of Partnership And Real World Data To Accelerate Patients Access To Innovative Treatment: The MENA Experience
Real World Evidence (RWE) continues to be a fundamental tool that touches all stakeholders across the entire healthcare system, guides their decision, and contributes to generating useful economic modeling. The Middle East and North Africa (MENA) region lacks data necessary for economic modeling. In this session, our panel of stakeholders will address 1) the current state (gaps and opportunities) of data sources in the MENA, 2) and how these gaps can be addressed through collaborations and research methodologies, reasonable with regard to cost, time, and resources, without compromising the robustness of evidence, 3) and how this approach could potentially accelerate patients access to innovative treatment that has not historically occurred in the MENA region.
Symposium sponsor is CCHO